Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 55Recurrence 7Lymphoma 6Neoplasms, Plasma Cell 5Immunoglobulin Light-chain Amyloidosis 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Paraproteinemias 2Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Leukemia, Myeloid, Acute 2beta-Thalassemia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thalassemia 1Sarcoma, Myeloid 1Prostatic Neoplasms 1Plasmablastic Lymphoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphadenopathy 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Biopsy 9Specimen Handling 8Magnetic Resonance Spectroscopy 6duvelisib 5Cyclophosphamide 5ruxolitinib 4Vincristine 410-propargyl-10-deazaaminopterin 4pembrolizumab 3X-Rays 3Prednisone 3Etoposide 3Doxorubicin 3tazemetostat 2sodium-iodide symporter 2cemiplimab 2belinostat 2Photons 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Immunoglobulin G 2Disulfides 2Cytarabine 2Bortezomib 2Azacitidine 2venetoclax 1talimogene laherparepvec 1romidepsin 1prednylidene 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × Bortezomib × 90 days × Clear all
NCT06390319 2026-05-01

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

St. Jude Children's Research Hospital

Phase 2 Recruiting
100 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02783625 2026-04-24

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
114 enrolled
Lymphoid

Lymphoma, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡